Essential Reads: Keeping Up with the Medical Literature in Reproductive Psychiatry
There are many different sources of information, some better than others.
New Oral Drug Zuranolone (Zurzuvae) for Postpartum Depression is Now Available
The FDA approves zuranolone, a new option for the treatment of PPD, a rapidly acting antidepressant with a good safety profile.
Cannabis Exposure and Adverse Pregnancy Outcomes, Possibility of Placental Insufficiency
In this multicenter cohort, maternal cannabis use documented using urine drug sampling was associated with increased risk of adverse pregnancy outcomes related to placental dysfunction.
Can We use the Electronic Health Record to Predict Risk for Postpartum Depression?
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
Toward a better framework for postmarketing reproductive safety surveillance of medications
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on zuranolone for postpartum depression with Ob.Gyn News on December 14, 2023.
Optimizing Cognitive Behavioral Interventions for Perinatal Depression
A wide range of delivery options may be effective for addressing symptoms of depression in perinatal individuals, and could therefore be leveraged to expand access to treatments.
Prediction of Postpartum Depression: Take a Closer Look at Question 3 on the PHQ-9
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
Using Metabolic Biomarkers to Predict Risk for Postpartum Depression
Metabolic biomarkers in the cerebrospinal fluid may be used to identify women at high risk for postpartum depression.